Nanoscope Therapeutics is advancing gene therapy using ambient light-sensitive molecules, bringing hope for renewed sight to millions of people blinded by retinal degenerative diseases for which no cure exists.
Jeff, a patient in our STARLIGHT Clinical Trial for Stargardt Macular Degeneration began to experience vision loss as a young boy. Today, Jeff is seeing more of the world and feeling positive about the future.
Roy, a patient in our RESTORE Clinical Trial for Retinitis Pigmentosa began to experience vision loss 20 years ago. After MCO-010 treatment Roy saw colors he had not seen in years and is now determined to participate in all aspects of his community.
Richard, a patient in our RESTORE Clinical Trial for Retinitis Pigmentosa, talks about the changes MCO-010 treatment has made in his life.
Hear how John, a patient in our RESTORE Clinical Trial for Retinitis Pigmentosa feels about his experience two years after being enrolled in the study.
Hear what a Stargardt Macular Degeneration patient in our STARLIGHT Clinical Trial has to say about her experience.
Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD.
Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope’s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells.
LEARN ABOUT OUR TECHNOLOGY
Our lead gene therapy product in clinical trials for retinitis pigmentosa will be the first therapy to correct the condition and is applicable for patients with complete or partial degeneration of the retina.
Pioneering a New Wave of Optogenetic Therapeutics for Vision Restoration
Nanoscope News & Events
-
Nanoscope Therapeutics Announces Participation in Upcoming ConferencesFebruary 21, 2024
-
Nanoscope to Moderate Discussions at the 4th Annual Gene Therapy Comparability SummitFebruary 14, 2024
-
Nanoscope Announces Presentation at the 68th Annual Biophysical Society MeetingFebruary 12, 2024
-
Nanoscope Therapeutics to Present at 47th Annual Macula Society MeetingFebruary 7, 2024
-
Nanoscope Therapeutics Announces Presentation at Bascom Palmer Eye Institute’s 21st Annual Angiogenesis, Exudation, and Degeneration MeetingFebruary 1, 2024
-
Nanoscope Therapeutics Provides Regulatory Update on MCO-010 for the Treatment of Retinitis PigmentosaJanuary 18, 2024
-
Nanoscope Therapeutics to Present at the 20th Annual Advanced Therapies Week ConferenceJanuary 12, 2024
-
Nanoscope Therapeutics Continues Leadership Growth; Welcomes Accomplished Finance and Biotech Leader Glenn Sblendorio as Chairman of the BoardDecember 4, 2023